Millennium Management
KALV

Millennium Management’s KalVista Pharmaceuticals KALV Stock Holding History

Millennium Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90,000
Closed -$1.02M – 6260
2025
Q2 		$1.02M Buy
+90,000
New +$1.1M ﹤0.01% 4393
2024
Q1 		– Sell
-50,000
Closed -$613K – 6430
2023
Q4 		$613K Buy
+50,000
New +$455K ﹤0.01% 4519

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management's KALV Position: Q1 2026 in Review

Millennium Management reduced its KalVista Pharmaceuticals (KALV) stake by 34% in Q1 2026, selling an estimated $15.9M and leaving 1,912,146 shares worth $38.5M. The position accounts for 0.02% of the portfolio, ranked #1032.

Millennium Management first reported a position in KALV in Q2 2016 and has held it in 25 quarters since. The position peaked at $46.8M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Millennium Management held 1,912,146 shares of KalVista Pharmaceuticals worth $38.5M as of Q1 2026.
  • Millennium Management sold 984,520 KalVista Pharmaceuticals shares in Q1 2026, an estimated $15.9M.
  • KalVista Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1032 holding.
  • Millennium Management first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 25 quarters since.
  • Millennium Management's KalVista Pharmaceuticals position peaked at $46.8M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.